Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism

Recommendation ID: IPG524/1
Question: NICE encourages further research into ultrasound-enhanced, catheter-directed
thrombolysis for pulmonary embolism. Ideally this should include comparative studies against catheter-directed thrombolysis alone. Patient selection should be documented. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.
Any explanatory notes (if applicable): The evidence on ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism raises no major safety concerns over those of catheter-directed thrombolysis (CDT) alone. With regard to efficacy, evidence of any enhancement of thrombolysis over CDT alone is inadequate in quality and quantity. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

Source guidance details

Comes from guidance: Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism
Number: IPG524
Date issued: June 2015

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No